Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abilify sNDA For Major Depressive Disorder Gets Priority Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol/Otsuka are seeking a broader indication for the atypical antipsychotic for MDD as adjunctive to antidepressant therapy.

You may also be interested in...



Bristol/Otsuka’s Abilify Gets FDA Nod For Use In Combination With Antidepressants

Aripiprazole becomes first drug approved as add-on treatment for major depressive disorder.

Bristol/Otsuka’s Abilify Gets FDA Nod For Use In Combination With Antidepressants

Aripiprazole becomes first drug approved as add-on treatment for major depressive disorder.

Abilify Approval For Teens Is Bristol/Otsuka’s Latest Step In Franchise Expansion

Approval of the atypical antipsychotic for schizophrenia patients ages 13-17 comes more than two months after J&J’s Risperdal was cleared for adolescent schizophrenia.

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel